1. TMC114/r in 3-class-experienced patients: 24-wk primary safety analysis of the Power 2 study (C202);Berger,2005
2. Aptivus prescribing information,2006
3. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy;Bozzette;New England Journal of Medicine,2001
4. Sustiva prescribing information,2005
5. Department of Health and Human Services. (2006, October). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved December 11, 2006, from http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=OfT&GuidelineID=7&ClassID=1.